Cencora/$COR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cencora
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Ticker
$COR
Sector
Primary listing
NYSE
Industry
Health Care Providers and Services
Headquarters
Employees
44,000
ISIN
US03073E1055
Website
Cencora Metrics
BasicAdvanced
$57B
34.11
$8.59
0.60
$2.16
0.75%
Price and volume
Market cap
$57B
Beta
0.6
52-week high
$309.35
52-week low
$218.65
Average daily volume
1.3M
Dividend rate
$2.16
Financial strength
Current ratio
0.873
Quick ratio
0.482
Long term debt to equity
737.419
Total debt to equity
827.73
Dividend payout ratio (TTM)
25.13%
Interest coverage (TTM)
9.44%
Profitability
EBITDA (TTM)
4,311.264
Gross margin (TTM)
3.29%
Net profit margin (TTM)
0.55%
Operating margin (TTM)
1.03%
Effective tax rate (TTM)
25.90%
Revenue per employee (TTM)
$7,050,000
Management effectiveness
Return on assets (TTM)
2.97%
Return on equity (TTM)
141.78%
Valuation
Price to earnings (TTM)
34.107
Price to revenue (TTM)
0.185
Price to book
48.1
Price to tangible book (TTM)
-3.38
Price to free cash flow (TTM)
16.016
Free cash flow yield (TTM)
6.24%
Free cash flow per share (TTM)
1,828.60%
Dividend yield (TTM)
0.74%
Forward dividend yield
0.75%
Growth
Revenue change (TTM)
12.18%
Earnings per share change (TTM)
-5.98%
3-year revenue growth (CAGR)
10.54%
10-year revenue growth (CAGR)
9.24%
3-year earnings per share growth (CAGR)
1.56%
10-year earnings per share growth (CAGR)
11.24%
3-year dividend per share growth (CAGR)
5.61%
10-year dividend per share growth (CAGR)
7.28%
What the Analysts think about Cencora
Analyst ratings (Buy, Hold, Sell) for Cencora stock.
Bulls say / Bears say
Cencora's acquisition of RCA enhances its position in high-growth specialty pharmaceutical markets, potentially driving significant revenue growth. (Investing.com)
The company's strong performance in the U.S. Healthcare sector, with a 14.69% revenue growth as of September 30, 2024, indicates robust operational efficiency and market demand. (Nasdaq)
Cencora's commitment to innovation, demonstrated by new products in inventory management and clinical trial support, positions it as a comprehensive partner in the pharmaceutical supply chain. (Investing.com)
BofA Securities downgraded Cencora's stock from Buy to Neutral, citing concerns over the company's ability to maintain double-digit EPS growth amid industry normalization. (Investing.com)
Cencora's high debt-to-equity ratio of 5.11 indicates a heavier reliance on borrowed funds, raising concerns about financial leverage and potential strain. (Benzinga)
The company's international segment has shown softer performance, with expectations of guidance reductions due to slow clinical trial activity, potentially impacting global growth prospects. (TipRanks)
Data summarised monthly by Lightyear AI. Last updated on 28 Jun 2025.
Cencora Financial Performance
Revenues and expenses
Cencora Earnings Performance
Company profitability
Cencora News
AllArticlesVideos
Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release
Business Wire·3 weeks ago
Cencora Elects Lori J. Ryerkerk to Its Board of Directors
Business Wire·2 months ago
Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings
Benzinga·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cencora stock?
Cencora (COR) has a market cap of $57B as of July 21, 2025.
What is the P/E ratio for Cencora stock?
The price to earnings (P/E) ratio for Cencora (COR) stock is 34.11 as of July 21, 2025.
Does Cencora stock pay dividends?
Yes, the Cencora (COR) stock pays dividends to shareholders. As of July 21, 2025, the dividend rate is $2.16 and the yield is 0.75%. Cencora has a payout ratio of 25.13% on a trailing twelve-month basis.
When is the next Cencora dividend payment date?
The next Cencora (COR) dividend payment date is unconfirmed.
What is the beta indicator for Cencora?
Cencora (COR) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.